跳至主要内容
临床试验/NCT02060890
NCT02060890已完成不适用

A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2014年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery

研究概览

简要总结

This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tumors.

详细描述

Patients with recurrent glioblastoma who are candidates for surgery for their clinical management will have tumor tissue taken at the time of surgery. Tissue samples will be obtained from the contrasting edge as well as infiltrating margins. Circulating tumor DNA will also be taken from blood samples before, and after surgery and every 2 months. Genomic profiling of the tumor tissue will be performed and a Molecular Tumor Board will review the profiling within 28 to 35 days of surgery. If specific potential targets are amenable to treatment, a treatment recommendation will be made. Up to 4 drugs could be suggested to the treating physician. The patient and the treating physician may or may not choose to use the recommendation. Any drug from the US Pharmacopeia may be chosen. If the treatment as suggested is given, patients will be followed for toxicity and efficacy, including progression and survival. If the treatment is not given, patients will be followed for progression and survival.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must understand and provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization prior to initiation of any study-specific procedures
  • Have a life expectancy of at least 3 months
  • Patients must have a diagnosis of histologically confirmed Glioblastoma that is felt on imaging to be progressive despite standard of care treatment
  • at least 18 years of age
  • Patient is a good medical candidate for a standard of care surgical procedure
  • Patients may enroll independent of number of prior therapies, but must have received prior radiation therapy
  • Patients must have a performance status (KPS) of at least 60.

排除标准

  • Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
  • Eligibility for treatment using the specialized Tumor Board recommendations
  • Patients must have fully recovered from any toxicity associated with surgery
  • Must begin treatment no longer than 35 calendar days from surgery
  • Must have KPS at least 60
  • Must have Absolute Neutrophil Count (ANC) at least 1500/mm3, platelets at least 125,000/mm2, Hg at least 8 gm/dl
  • Must have electrolytes (Na, K, Co2, Cl) within normal limits using institutional guidelines
  • Must have baseline MRI within 14 days prior to starting cycle 1, day 1 of treatment (+/- 3 days)
  • Additional laboratory guidelines will be based upon therapies suggested by the specialized Tumor Board based upon anticipated, known toxicities of those agents and must be within at least 1.5 x upper normal limits of institutional normal limits
  • Patient must agree to follow the recommended treatment regimen, including clinic visits, laboratory, imaging, and toxicity assessments

结局指标

主要结局

Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery

时间窗: 35 days from surgery to making genomic informed treatment recommendation

To demonstrate feasibility, we would want the treatment recommendation to be fully complete within 35 calendar days in at least 85% of patients for which sufficient RNA and DNA is available.

次要结局

  • Number of Patients Who Chose to Pursue Treatment(Within 35 days from surgery to making genomic informed treatment recommendation)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验